Sören Reinke
Dr.
Postdoctoral Research Fellow in Immunology
Milicic Group
I studied Biology (BSc) and Molecular and Cell Biology (MSc) at the Freie Universität Berlin. This was followed by post-graduate studies at the Dresden University of Technology, investigating the mechanisms underlying rare auto-inflammatory diseases using pre-clinical mouse models. In 2020, after obtaining a PhD in Immunology, I joined the Vaccine Formulation and Adjuvants Group led by Dr Anita Milicic at the Jenner Institute in Oxford, working on the development of new adjuvanted vaccines. In close collaboration with the Vaccine Formulation Institute (VFI) in Geneva, we are investigating the mechanism of action of novel adjuvants in clinical development, in particular at the intersection of innate and adaptive immune responses. Using a malaria vaccine and a murine model system, we are characterising the innate and adaptive immune activation in a spatio-temporal manner, with the analysis of cellular and molecular events at the site of injection, draining lymph nodes, peripheral blood, spleen, and liver. Using this experimental approach, we aim to uncover the precise mechanism of clinically relevant adjuvant-induced immune activation and the resulting interplay between innate and adaptive immunity. The overarching goal of our studies is to facilitate efficient development of new vaccines through mechanistically informed ‘intelligent’ vaccine design.
Recent publications
-
RIP2-deficiency induces inflammation in response to SV40 Large T induced genotoxic stress through altered ROS homeostasis
Kapplusch F. et al, (2022), Clinical Immunology, 108998 - 108998
-
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.
Luchner M. et al, (2021), Pharmaceutics, 13
-
A Kinetic Response Model for Standardized Regression Analyses of Inflammation-Triggered Hypothermic Body Temperature-Time Courses in Mice.
Diebner HH. et al, (2021), Frontiers in physiology, 12
-
Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
Reinke S. et al, (2020), Vaccines, 8, 554 - 554
-
Non-canonical Caspase-1 Signaling Drives RIP2-Dependent and TNF-α-Mediated Inflammation In Vivo.
Reinke S. et al, (2020), Cell Rep, 30, 2501 - 2511.e5
-
An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes.
Grinstein L. et al, (2018), Clin Immunol, 191, 100 - 109
-
Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.
Riemer P. et al, (2015), Oncogene, 34, 3164 - 3175